Abstract
Type III Secretion System (TTSS) is a key pathogenicity factor of Pseudomonas aeruginosa. The suppression of the activity of TTSS would potentially allow block the infection independently on the presence of antimicrobial resistance. To study the role of TTSS P. аeruginosa in the development of nosocomial infections we characterized genes coding TTSS effector proteins and the activity of its secretion in vitro in 75 P. аeruginosa isolates. Genes of TTSS effectors were detected in all studied isolates with exoS+-genotype being the predominant one (80%). Isolates with exoU+-genotype were revealed twice more frequent from urine and blood than from respiratory material: 26.5% vs 12.8%. The presence of functional TTSS during the induction by low calcium concentrations was observed for 60.4% of isolates. At the same time 76.6% of strains were highly cytotoxic in vitro. Exploring the relation of TTSS-genotypes with resistance to particular groups of antimicrobials has shown higher resistance rates to gentamicin and ciprofloxacin in exoU+-genotype. Overall we can conclude that TTSS is a potentially interesting target for control of infections caused by multi-resistant P. аeruginosa strains.
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
Research Institute for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia
-
1.
Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;3:351-68.
-
2.
Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999;104:743-50.
-
3.
Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nature Reviews Microbiology 2012;12:841-51.
-
4.
Zychlinsky A, Kenny B, Ménard R, Prévost MC, Holland IB, Sansonetti PJ. IpaB mediates macrophage apoptosis induced by Shigella flexneri. Mol Microbiol 1994;11:619-27.
-
5.
Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiol 2001;147:2659-69.
-
6.
Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001;183:1767-74.
-
7.
Diaz MH, Hauser AR. Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytis cells during acute pneumonia. Infect Immun 2010;78:1447-56.
-
8.
Allewelt, Coleman FT, Grout M, Priebe GP, Pier G. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 2000;68:3998-4004.
-
9.
Schulert GS, Feltman H, Rabin SD, Martin CG, Battle SE, Hauser AR. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 2003;188:1695-706.
-
10.
Sawa T, Shimizu M, Moriyama K, Wiener-Kronish JP. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Crit Care 2014;18(6):668.
-
11.
Yahr TL, Wolfgang MC. Transcriptional regulation of the Pseudomonas aeruginosa type III secretion system. Mol Microbiol 2006;62(3):631-40.
-
12.
Hauser AR. The Type III Secretion System of Pseudomonas aeruginosa: Infection by Injection. Nat Rev Microbiol 2009;7(9):654-65.
-
13.
Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, Rello J. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002;30:521-8.
-
14.
Torrens G, Cabot G, Ocampo-Sosa AA, Conejo MC, Zamorano L, Navarro F, et al. Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant β-lactam resistance mechanisms. Antimicrob Agents Chemother 2016;60(10):6407-10.
-
15.
Mitov I, Strateva T, Markova B. Prevalence of virulence genes among Bulgarian nosocomial and cystic fibrosis isolates of Pseudomonas aeruginosa. Braxilian J Microbiol 2010;41:588-95.
-
16.
Garey KW, Vo OP, Larocco MT, Tam VH. Prevalence of type III protein exoenzymes and antimicrobial suceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother 2008;20:714-20.
-
17.
Wong Beringer A, Wiener-Kronish JP, Lunch S, Flanagan J. Comparison of type III secretion system virulence among fluoroguinolone-susceptible and resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008;14:330-6.
-
18.
Agnello M, Wong-Beringer A. Differentiation in guinolone resistance by virulence genotype in Pseudomonas aeruginosa. Plos One 2012;7:e42973.
-
19.
Menshikov VV (Ed.), 2003. Clinical laboratory analytics. Volume IV. Analytical technologies in the clinical laboratory. Moscow: Agat-Med.
-
20.
Ajayi T, Allmond LR, Sawa T, Wiener-Kronish JP. Single-nucleotidepolymorphism mapping of the Pseudomonas aeruginosa type III secretion toxins for development of a diagnostic multiplex PCR system. J Clin Microbiol 2003;41(8):3526-31.
-
21.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
-
22.
Sawa T. The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response. J Intensive Care 2014;2(1):10.
-
23.
Dasgupta N, Ashare A, Hunninghake GW, Yahr TL. Transcriptional induction of the Pseudomonas aeruginosa type III secretion system by low Ca2+ and host cell contact proceeds through two distinct signaling pathways. Infect Immun 2006;74(6):3334-41.
-
24.
Lee VT, Smith RS, Tümmler B. Activities of Pseudomonas aeruginosa effectors secreted by the type III secretion system in vitro and during infection. Infect Immun 2005;73(3):1695-705.
-
25.
Schulert GS, Feltman H, Rabin SD, Martin CG, Battle SE, Hauser AR. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 2003;188:1695-706.
-
26.
Jabalameli F, Mirsalehian A, Khoramian B, et al. Evaluation of biofilm production and characterization of genes encoding type III secretion system among Pseudomonas aeruginosa isolated from burn patients. Burns 2012;38:1192-7
-
27.
Kuznetsova МV, Maksimova АV, Karpunina ТI, Demakov VA. Prevalence of cytotoxicity effectors in nosocomial Pseudomonas aeruginosa strains. J Microbiol Epidemiol Immunobiol 2014;6:9-14.